Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599910 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1HTT | |
| SCHEMBL5359167 | 1.00 | MEN1 (0.58) | MEN1KMT2ATSHRMAPK1HTT | |
| SCHEMBL39142 | 0.95 | — | — | |
| Flurothyl SCHEMBL1718049 | 0.92 | TSHR (0.56) | MEN1KMT2ATSHRMAPK1HTT | |
| SCHEMBL1718051 | 0.86 | CA1 (0.33) | MEN1KMT2AHTTALDH1A1EPHX2 | |
| SCHEMBL19946674 | 0.86 | CA1 (0.33) | MEN1KMT2AHTTALDH1A1EPHX2 | |
| SCHEMBL19946677 | 0.86 | CA1 (0.33) | MEN1KMT2AHTTALDH1A1EPHX2 | |
| SCHEMBL26110987 | 0.86 | CA1 (0.33) | MEN1KMT2AHTTALDH1A1EPHX2 | |
| SCHEMBL1591167 | 0.83 | CA1 (0.35) | HTTALDH1A1EPHX2 | |
| SCHEMBL9588443 | 0.81 | MEN1 (0.32) | MEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354966-B2 | Non-fluorinated or low fluorine content internal salts of glycerol 2-aminoethyl phosphates; use in aerosols for inhalants for treating asthma, chronic obstructive pulmonary disease and rhinitis | GLAXO GROUP LIMITED (GB) | 2008-04-08 | — | — | US | disclosed |
| US-7217409-B2 | Alkanoic acid derivatives | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050287076-A1 | Compounds for use as surfactants | GLAXO GROUP LIMITED (GB) | 2005-12-29 | — | — | US | disclosed |
| EP-1480990-B1 | COMPOUNDS FOR USE AS SURFACTANTS | GLAXO GROUP LTD (GB) | 2005-11-09 | — | — | EP | disclosed |
| EP-1480990-A1 | COMPOUNDS FOR USE AS SURFACTANTS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-20040067202-A1 | Novel alkanoic acid derivaties | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | US | disclosed |
| WO-2003074537-A1 | COMPOUNDS FOR USE AS SURFACTANTS | GLAXO GROUP LIMITED (GB) | 2003-09-12 | — | — | WO | disclosed |
| EP-1318973-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024623-A2 | NOVEL ALKANOIC ACID DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067202-A1 | Novel alkanoic acid derivaties | ALK, FFAR1, FFAR3 | MEN1 2802/4885KMT2A 3498/4885TSHR 2123/4885 |
| US-20050287076-A1 | Compounds for use as surfactants | SGMS1, SGMS2, PHOSPHO1 | MEN1 1162/4885KMT2A 4777/4885TSHR 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.